Johnson & Johnson Coronavirus Vaccine Generates Lasting Immune Response in Clinical Trial
Johnson & Johnson’s coronavirus vaccine generated a lasting immune response to the deadly bug in an early-stage clinical trial, the pharmaceutical giant said.
More than 90 percent of the study’s 805 participants had neutralizing antibodies offering protection against COVID-19 29 days after receiving a single dose of the vaccine, the New Jersey-based drugmaker said Wednesday.
The antibodies stuck around for at least 71 days among the participants ranging in age from 18 to 55 years old, according to interim results published in the New England Journal of Medicine. J&J said it will have data later this month on the durability of immunity in people older than 65.
The early data showed signs of promise for Johnson & Johnson’s one-shot vaccine even as the company reportedly hit a snag in producing the inoculations.
